HomeNewsBrilinta

Brilinta

Jump to

AstraZeneca launches heart drug Brilinta in India

AstraZeneca Pharma India today launched its patented antiplatelet drug Brilinta, used to prevent heart attack, after receiving approval from the Drug Controller General of India (DCGI).
Dishman Pharma expects 15% consolidated growth, says CFO

In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Brilinta

AstraZeneca launches heart drug Brilinta in India

Dishman Pharma expects 15% consolidated growth, says CFO